Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goserelin - AstraZeneca

Drug Profile

Goserelin - AstraZeneca

Alternative Names: Goserelin acetate - AstraZeneca; Goserelin acetate implant - AstraZeneca; ZD-9393; Zoladex

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action LHRH receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 07 May 2024 Health Canada approves sNDA for Goserelin 10.8mg every 12 weeks for the treatment of Breast cancer (Late-stage disease)
  • 05 Feb 2024 The National Comprehensive Cancer Network® Breast Cancer Panel includes a category 2A recommendation for goserelin for hormone receptor positive (HR+) Breast cancer and Ovarian cancer
  • 24 Oct 2023 The National Comprehensive Cancer Network® Head and Neck Cancers panel includes a category 2B recommendation for goserelin for salivary gland cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top